C82.19
Follicular lymphoma grade II, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Follicular lymphoma is a type of cancer that begins in the lymphatic system, specifically within the follicular cells of lymph nodes. Grade II indicates a moderate level of aggressiveness, meaning the disease grows at a rate between the indolent (slow-growing) grade I and the more aggressive grade III. When this lymphoma occurs in extranodal sites (areas outside of lymph nodes, such as organs) and solid organs, it can affect various parts of the body beyond the traditional lymphatic system. Understanding this specific diagnosis helps in guiding treatment options and prognosis.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal cell growth in lymphatic tissue Certain inherited conditions or genetic predispositions Environmental exposures, such as chemicals or radiation (though less clearly established) Infections that might be associated with lymphoid tissue changes (e.g., viral infections, though not directly causative)
Key Symptoms: Swollen lymph nodes that are painless and may be palpable in the neck, armpits, or groin Fatigue or weakness Unexplained weight loss Fever or night sweats Enlargement of organs such as the spleen or liver, leading to discomfort or fullness Abdominal pain or swelling (if organs like the stomach or intestines are involved) Itching or skin changes (less common)
Diagnostic & Treatment
Diagnosis Path: Diagnosing follicular lymphoma involves multiple steps, including physical examinations, imaging tests such as CT or PET scans, and laboratory analysis. A definitive diagnosis usually requires a biopsy of affected tissue, where pathologists examine the tissue under a microscope to identify characteristic cancer cells. Additional blood tests might be performed to assess overall health and organ function. Staging the disease, which involves determining the extent of its spread, is essential for planning treatment.
Treatment Protocols: Observation (watchful waiting) for some patients with slow disease progression Chemotherapy, often combined with immunotherapy (e.g., monoclonal antibodies like rituximab) Targeted therapy aimed at specific molecules involved in lymphoma growth Radiation therapy for localized disease In cases of advanced or refractory disease, stem cell transplantation may be considered Supportive care to manage symptoms and side effects
Clinical Advice & FAQs
Billing Guidance
Is C82.19 a billable ICD-10 code?
Yes, C82.19 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C82.19?
Clinical documentation must specify the nature of Follicular lymphoma grade II, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference